Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis

RECOMMENDED

Immunotherapy

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

doi: smw.2019.14697.

Immunotherapy

Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics

Nanomedicine (Lond).

Grimaldi AM, Incoronato M, Salvatore M, Soricelli A

doi: 10.2217/nnm-2017-0208.

Melanoma and Skin CancerImmunotherapy

Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy

Biomaterials

Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, Ferguson DM, Griffith TS, Panyam J

doi: 10.1016/j.biomaterials.

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

Crit Rev Oncol Hematol.

Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, Scartozzi M, Saba L

doi: 10.1016/

Immunotherapy

Immunotherapy in Gastrointestinal Cancers

Biomed Res Int.

Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S

doi: 10.1155/2017/4346576.

Melanoma and Skin CancerImmunotherapy

Identification of essential genes for cancer immunotherapy

Nature.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP

doi: 10.1038/nature23477.

T Cells

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Semin Cancer Biol.

Kumar P, Saini S, Prabhakar BS

doi: 10.1016/j.semcancer.

Immunotherapy

Novel immunotherapy strategies for hepatobiliary cancers

Immunotherapy.

DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ

doi: 10.2217/imt-2018-0024.

ImmunotherapyImmunomodulation

Synthetic immune niches for cancer immunotherapy

Nat Rev Immunol.

Weiden J, Tel J, Figdor CG

doi: 10.1038/nri.2017.89.

Related content

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics

Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

Immunotherapy in Gastrointestinal Cancers

Identification of essential genes for cancer immunotherapy

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Novel immunotherapy strategies for hepatobiliary cancers

Synthetic immune niches for cancer immunotherapy